Compound: Farglitazar
SMILES: O=C(c1c(N[C@H](C(=O)O)Cc2ccc(OCCc3nc(-c4ccccc4)oc3C)cc2)cccc1)c5ccccc5
InChIKey: ZZCHHVUQYRMYLW-HKBQPEDESA-N
Synonyms: Farglitazar, 196808-45-4, GI-262570, GI262570, GI262570X, GI-262570X, DTXSID1047310, GI2570, GI-2570, 3433GY7132, DTXCID9027310, G1-262570, (2S)-2-((2-(benzoyl)phenyl)amino)-3-(4-(2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy)phenyl)propanoic acid, (2S)-2-[[2-(benzoyl)phenyl]amino]-3-[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]propanoic acid, FARGLITAZARUM, RefChem:921467, GI 262570, (S)-2-((2-Benzoylphenyl)amino)-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic acid, CHEMBL107367, (2S)-2-(2-benzoylanilino)-3-[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]propanoic acid, 2-(2-BENZOYL-PHENYLAMINO)-3-{4-[2-(5-METHYL-2-PHENYL-OXAZOL-4-YL)-ETHOXY]-PHENYL}-PROPIONIC ACID, L-Tyrosine, N-(2-benzoylphenyl)-o-(2-(5-methyl-2-phenyl-4-oxazolyl)ethyl)-, N-(o-Benzoylphenyl)-O-(2-(5-methyl-2-phenyl-4-oxazolyl)ethyl)-L-tyrosine, Farglitazar [USAN], N-(2-Benzoylphenyl)-O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]-L-tyrosine, Farglitazar [USAN:INN], L-tyrosine, N-(2-benzoylphenyl)-O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]-, UNII-3433GY7132, GI 2570, 1fm9, FARGLITAZAR [INN], Farglitazar (USAN/INN), GI262570; Farglitazar, FARGLITAZAR [WHO-DD], KBioGR_002347, KBioSS_002350, G1 262570; GI 262570; GI 262570X, SCHEMBL501024, GTPL2672, orb1700621, KBio2_002347, KBio2_004915, KBio2_007483, CHEBI:229920, cMAP_000025, ZZCHHVUQYRMYLW-HKBQPEDESA-N, GLXC-07306, Tox21_300218, BDBM50085044, AKOS027326860, L-Tyrosine, N-(2-benzoylphenyl)-o-(2-(5-methyl-2-phenyl-4-oxazolyl)ethyl), GI 262570X, NCGC00247940-01, NCGC00254050-01, DA-63375, HY-105074, CAS-196808-45-4, CS-0024894, NS00127403, D04132, Q5435087, L-Tyrosine, N-(2-benzoylphenyl)-O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]- (9CI), N-(2-benzoylphenyl)-O-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethyl]-L-tyrosine, O-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethyl]-N-[2-(phenylcarbonyl)phenyl]-L-tyrosine, (S)-2-((2-Benzoylphenyl)amino)-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoicacid, (S)-2-(2-Benzoyl-phenylamino)-3-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-phenyl}-propionic acid, (S)-2-(2-benzoylphenylamino)-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic acid, 2-(2-Benzoyl-phenylamino)-3-{4-[2-(5-methyl-2-phenyl-oxazol-4-yl)-ethoxy]-phenyl}-propionic acid(GI 262570)
Theoretical properties:
molecular_formula: C34H30N2O5
molecular_weight: 546.6 g/mol
exact_mass: 546.21547206 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 2
hydrogen_bond_acceptor_count: 7
rotatable_bond_count: 12
heavy_atom_count: 41
topological_polar_surface_area: 102 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
Descriptions:
pubchem: Farglitazar is a phenylalanine derivative.
chembl: FARGLITAZAR is a small molecule listed in the ChEMBL database and has reached clinical trial phase 2.0.
wikipedia: Farglitazar is a peroxisome proliferator-activated receptor agonist which was formerly under development by GlaxoSmithKline, but has never been marketed.  It progressed to phase II clinical trials for the treatment of hepatic fibrosis, but failed to show efficacy. After reaching phase III for type 2 diabetes, further development was discontinued.